BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu Z, Liu X, Liang J, Liu Y, Hou X, Zhang M, Li Y, Jiang X. Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects. Front Immunol 2021;12:765101. [PMID: 34675942 DOI: 10.3389/fimmu.2021.765101] [Cited by in Crossref: 18] [Cited by in F6Publishing: 25] [Article Influence: 18.0] [Reference Citation Analysis]
Number Citing Articles
1 Han H, Jin W, Li X. Mesenchymal stem cells-based therapy in liver diseases. Mol Biomed 2022;3:23. [DOI: 10.1186/s43556-022-00088-x] [Reference Citation Analysis]
2 Gong D, Li S, Yu Z, Wang K, Qiao X, Wu C. Contribution of PNPLA3 gene polymorphisms to hepatocellular carcinoma susceptibility in the Chinese Han population. BMC Med Genomics 2022;15:248. [DOI: 10.1186/s12920-022-01394-7] [Reference Citation Analysis]
3 Wang Y, Qian J, Xu W, Wang J, Li Z, Tan G, Suo A. Polysaccharide Nanodonuts for Photochemotherapy‐Amplified Immunogenic Cell Death to Potentiate Systemic Antitumor Immunity Against Hepatocellular Carcinoma. Adv Funct Materials 2022. [DOI: 10.1002/adfm.202208486] [Reference Citation Analysis]
4 Ouranos K, Chatziioannou A, Goulis I, Sinakos E. Role of immunotherapy in downsizing hepatocellular carcinoma prior to liver transplantation. World J Transplant 2022; 12(11): 331-346 [DOI: 10.5500/wjt.v12.i11.331] [Reference Citation Analysis]
5 Shi H, Liang C, Yao C, Gao Z, Qin J, Cao J, Zhang M, Li Y, Wang M, Sun H, Xie S, Fang D. Elevation of spermine remodels immunosuppressive microenvironment through driving the modification of PD-L1 in hepatocellular carcinoma. Cell Commun Signal 2022;20:175. [DOI: 10.1186/s12964-022-00981-6] [Reference Citation Analysis]
6 Aghayev T, Titerina EK, Khoreva MV, Gankovskaya LV. Role of cytokines in hepatocellular carcinoma. Med immunol 2022;24:889-902. [DOI: 10.15789/1563-0625-roc-2512] [Reference Citation Analysis]
7 Rizzo A, Ricci AD, Brandi G. Trans-Arterial Chemoembolization Plus Systemic Treatments for Hepatocellular Carcinoma: An Update. JPM 2022;12:1788. [DOI: 10.3390/jpm12111788] [Reference Citation Analysis]
8 Kazemi MH, Sadri M, Najafi A, Rahimi A, Baghernejadan Z, Khorramdelazad H, Falak R. Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango? Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1018962] [Reference Citation Analysis]
9 Shen Q, He Y, Qian J, Wang X. Identifying tumor immunity-associated molecular features in liver hepatocellular carcinoma by multi-omics analysis. Front Mol Biosci 2022;9:960457. [DOI: 10.3389/fmolb.2022.960457] [Reference Citation Analysis]
10 Wang J, Shen B, Liu X, Zhang S, Yang C, Zheng Q, Hao Y, Jiang J. An Immunogenic Cell Death-Related Classification Predicts Prognosis and Response to Immunotherapy in Hepatocellular carcinoma.. [DOI: 10.21203/rs.3.rs-2139514/v1] [Reference Citation Analysis]
11 Liu K, Wu J, Xu Y, Li D, Huang S, Mao Y. . OTT 2022;Volume 15:1079-94. [DOI: 10.2147/ott.s383685] [Reference Citation Analysis]
12 Kim D. Combination of interventional oncology local therapies and immunotherapy for the treatment of hepatocellular carcinoma. J Liver Cancer 2022;22:93-102. [DOI: 10.17998/jlc.2022.03.28] [Reference Citation Analysis]
13 Rizzo A, Ricci AD. Challenges and Future Trends of Hepatocellular Carcinoma Immunotherapy. IJMS 2022;23:11363. [DOI: 10.3390/ijms231911363] [Reference Citation Analysis]
14 da Cruz NS, Pasquarelli-do-nascimento G, e Oliveira ACP, Magalhães KG. Inflammasome-Mediated Cytokines: A Key Connection between Obesity-Associated NASH and Liver Cancer Progression. Biomedicines 2022;10:2344. [DOI: 10.3390/biomedicines10102344] [Reference Citation Analysis]
15 Zhang W, Wan Y, Zhang Y, Liu Q, Zhu X. CSTF2 Acts as a Prognostic Marker Correlated with Immune Infiltration in Hepatocellular Carcinoma. Cancer Manag Res 2022;14:2691-709. [PMID: 36117731 DOI: 10.2147/CMAR.S359545] [Reference Citation Analysis]
16 Wang X, Li Y, Li Y, Liu P, Liu S, Pan Y, Marchese C. FBXW7 Reduces the Cancer Stem Cell-Like Properties of Hepatocellular Carcinoma by Regulating the Ubiquitination and Degradation of ACTL6A. Stem Cells International 2022;2022:1-26. [DOI: 10.1155/2022/3242482] [Reference Citation Analysis]
17 Zhang Y, Pang S, Sun B, Zhang M, Jiao X, Lai L, Qian Y, Yang N, Yang W. ELOVLs Predict Distinct Prognosis Value and Immunotherapy Efficacy In Patients With Hepatocellular Carcinoma. Front Oncol 2022;12:884066. [DOI: 10.3389/fonc.2022.884066] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Wang F, Cheng F, Zheng F. Stem cell like memory T cells: A new paradigm in cancer immunotherapy. Clin Immunol 2022;241:109078. [PMID: 35840054 DOI: 10.1016/j.clim.2022.109078] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Li D, Xie Y, Sun J, Zhang L, Jiang W, Yang D. LncRNA ZNF674-AS1 Hinders Proliferation and Invasion of Hepatic Carcinoma Cells through the Glycolysis Pathway. Journal of Oncology 2022;2022:1-9. [DOI: 10.1155/2022/8063382] [Reference Citation Analysis]
20 Zhao H, Liu H, Yang Y, Wang H. The Emerging Role of EVA1A in Different Types of Cancers. Int J Mol Sci 2022;23:6665. [PMID: 35743108 DOI: 10.3390/ijms23126665] [Reference Citation Analysis]
21 Wang T, Dai L, Shen S, Yang Y, Yang M, Yang X, Qiu Y, Wang W. Comprehensive Molecular Analyses of a Macrophage-Related Gene Signature With Regard to Prognosis, Immune Features, and Biomarkers for Immunotherapy in Hepatocellular Carcinoma Based on WGCNA and the LASSO Algorithm. Front Immunol 2022;13:843408. [DOI: 10.3389/fimmu.2022.843408] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
22 Liu Y, Li R, Wang X, Xue Z, Yang X, Tang B. Comprehensive Analyses of MELK-Associated ceRNA Networks Reveal a Potential Biomarker for Predicting Poor Prognosis and Immunotherapy Efficacy in Hepatocellular Carcinoma. Front Cell Dev Biol 2022;10:824938. [DOI: 10.3389/fcell.2022.824938] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Wang Q, Tang Y, Ge Y, Zhang S, Zheng M. Long non-coding RNA NRAV enhances proliferation and invasion of hepatocellular carcinoma cells by modulating the Wnt/β-catenin signaling pathway. Bioengineered 2022;13:10026-37. [PMID: 35436415 DOI: 10.1080/21655979.2022.2062977] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Zhu S, Liu C, Dong Y, Shao J, Liu B, Shen J. A Retrospective Study of Lenvatinib Monotherapy or Combined With Programmed Cell Death Protein 1 Antibody in the Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma in China. Front Oncol 2021;11:788635. [PMID: 34976828 DOI: 10.3389/fonc.2021.788635] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Tian S, Hu Y, Yang C, Yu J, Liu J, Xuan G, Liu Y, Sun K, Zhang M, Ma S, Shang Y, Zhou X, Han Y; State Key Laboratory of Cancer Biology, Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xi'an 710032, China, Department of Radiation Oncology, Xijing Hospital, The Fourth Military Medical University, Xi'an 710032, China, Department of Gastroenterology, The Air Force Hospital from Eastern Theater of PLA, Nanjing 210002, China. . MBE 2022;19:4719-36. [DOI: 10.3934/mbe.2022220] [Reference Citation Analysis]
26 Lin JC, Liu TP, Andriani V, Athoillah M, Wang CY, Yang PM. Bioinformatics Analysis Identifies Precision Treatment with Paclitaxel for Hepatocellular Carcinoma Patients Harboring Mutant TP53 or Wild-Type CTNNB1 Gene. J Pers Med 2021;11:1199. [PMID: 34834551 DOI: 10.3390/jpm11111199] [Cited by in F6Publishing: 1] [Reference Citation Analysis]